Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world
Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions.
Viatris Inc. is a wholly owned subsidiary of Pfizer that specializes in off-patent drugs. Share price fell about 4% in the past year from $11.88 to $11.41, as of Thursday’s market close.
Robert F. Kennedy, Jr. will begin Senate confirmation hearings on Wednesday as President Donald Trump's pick to lead the Department of Health and Human Services.
Market Alert: PESG Releases New Report Highlighting Silexion Therapeutics as an Emerging Leader in the Multi-Billion Dollar Precision Oncology Industry
Pfizer Inc. (NYSEPFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February 13-15 in San Francisco, California. Data from more than 20 company-sponsored, investigator-sponsored, and collaborative research abstracts, including five oral presentations, highlight advancements in developing new standards of care within prostate and bladder cancer across the company’s core scientific modalities, including small molecules and antibody-drug conjugates.
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald Trump's executive order to withdraw from the global health body.
Pfizer Inc (NYSEPFE) shares are trading higher Monday. Some of the optimism may be surrounding activist Starboard Value's decision to not pursue a proxy battle with the company.
U.S. Vice President JD Vance acknowledged Sunday that Americans will need to wait before seeing relief from high grocery prices, despite the President Donald Trump administration's flurry of executive orders in its first week back in office.
The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force dedicated to the development of a clear and comprehensive regulatory framework for crypto assets.
The S&P 500 index has done well over the years. Companies like Walgreens, Pfizer, and Ford are high-yielding. Other high-yielding S&P 500 index stocks are Altria and Franklin Resources.
Pfizer Inc. (NYSEPFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. At the time of this analysis, the BRAFTOVI combination regimen demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) assessed by blinded independent central review (BICR) compared to patients receiving chemotherapy with or without bevacizumab (60.9% vs 40.0%, odds ratio =2.443, p=0.0008). These results will be presented today in an oral presentation (Abstract 16) at the 2025 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI) and were simultaneously published in Nature Medicine.
